Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method

Nanomedicine

Volumn 9, Issue 12, 2014, Pages 1821-1833

  Tshweu, Lesego ^a   Katata, Lebogang ^a,b   Kalombo, Lonji ^a   Chiappetta, Diego A ^c,d   Hocht, Christian ^c   Sosnik, Alejandro ^c,d,e   Swai, Hulda ^a  

^a DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Efavirenz ; Hiv ; In vitro drug release ; Oral bioavailability enhancement ; Poly(epsilon caprolactone) nanoparticle ; Spray drying

Indexed keywords

EFAVIRENZ; NANOCARRIER; NANOPARTICLE; POLYCAPROLACTONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; NANOCAPSULE; POLYESTER; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; ELIMINATION RATE CONSTANT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDRODYNAMICS; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRODUCTIVITY; RAT; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; MEDICINAL CHEMISTRY; NANOMEDICINE; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; ULTRASTRUCTURE; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; BENZOXAZINES; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; MALE; MICROSCOPY, ELECTRON, SCANNING; NANOCAPSULES; NANOMEDICINE; NANOTECHNOLOGY; PARTICLE SIZE; POLYESTERS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84908258289     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/NNM.13.167     Document Type: Article

References (64)

1. Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv. Drug Deliv. Rev. 62, 478-490 (2010).
2. Look M, Bandyopadhyay A, Blum JS, Fahmy JM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv. Drug Deliv. Rev. 62, 378-393 (2010).
3. Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug Deliv. Rev. 62, 503-517 (2010).
4. das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv. Drug Deliv. Rev. 62, 458-477 (2010). •• Thorough review of the main nanotechnology approaches to improve the pharmacotherapy of HIV.
5. Clercq ED. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 33, 307-320 (2009).
6. Alcaro S, Alteri C, Artese A et al. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist. Updat. 14, 141-149 (2011).
7. Sosnik A, Chiappetta DA, Carcaboso AM. Drug delivery in HIV pharmacotherapy: what has been done and the challenges standing ahead. J. Control. Release 138, 2-15 (2009). •• Comprehensive state-of-the-art review on the most relevant attemps to develop drug-delivery systems in HIV.
8. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. J. Am. Med. Assoc. 296, 827-843 (2006).
9. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV infected adults with antiretroviral therapy. HIV Med. 7, 487-496 (2006).
10. Wong SM, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int. J. Pharm. 317, 61-68 (2006).
11. Kesisoglou F, Panmai S, Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59, 631-644 (2007).
12. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 12, 1068-1075 (2007).
13. Sachs-Barrable K, Lee SD, Wasan EK, Thomton SJ, Wasan KM. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv. Drug Deliv. Rev. 60, 692-701 (2008).
14. Jyothi NVN, Prasanna PM, Sakarkar SN, Prabha KS, Ramaiah PS, Srawan GY. Microencapsulation techniques, factors influencing encapsulation efficiency. J. Microencap. 27, 187-197 (2010).
15. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 75, 1-18 (2010).
16. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and application torward targeted drug delivery. Nanomedicine 6, 9-24 (2010).
17. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70, 1-20 (2001).
18. Woodruff MA, Hutmacher DW. The return of a forgotten polymer - polycaprolactone in the 21st century. Prog. Polym. Sci. 35, 1217-1256 (2010).
19. Dash TK, Konkimalla VB. Poly-ε-caprolactone based formulations for drug delivery and tissue engineering: a review. J. Control. Release 158, 15-33 (2012).
20. Maurin MB, Rowe SM, Blom K, Pierce ME. Kinetics and mechanism of hydrolysis of efavirenz. Pharm. Res. 19, 517-521 (2002).
21. Chiappetta DA, Hocht C, Taira C, Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability. Nanomedicine (Lond.) 5, 11-23 (2010). • First pharmacokinetic study of nanoencapsulated efavirenz.
22. Williams I, Ruiter AD, Fisher M, Gazzard B, Leen C, Palfreeman A. British HIV Association (BHIVA) Guideline Development Manual British HIV Association. HIV Med. 7, 487-496 (2011).
23. Chiappetta DA, Hocht C, Taira C, Sosnik A. Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. Biomaterials 32, 2379-2387 (2011).
24. Chiappetta DA, Hocht C, Opezzo JAW, Sosnik A. Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (Lond.) 8, 223-237 (2013).
25. Katata L, Tshweu L, Naidoo S, Kalombo L, Swai H. Design and formulation of nano-sized spray dried efavirenz - part I: influence of formulation parameters. J. Nanopart. Res. 14, Art. 1247 (2012). • First report on the nanoencapsulation of efavirenz within polymeric nanoparticles.
26. Chiappetta DA, Sosnik A. Poly(ethylene oxide) - poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur. J. Pharm. Biopharm. 66, 303-317 (2007).
27. Semete B, Booysen L, Lemmer Y et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 6, 662-671 (2010).
28. Chiappetta DA, Alvarez-Lorenzo C, Rey-Rico A, Taboada P, Concheiro A, Sosnik A. N-alkylation of poloxamines modulates micellar encapsulation and release of the antiretroviral efavirenz. Eur. J. Pharm. Biopharm. 76, 24-37 (2010).
29. Chiappetta DA, Facorro G, Rubin de Celis E, Sosnik A. Synergistic encapsulation of the anti-HIV agent efavirenz within poly(ethylene oxide) - poly(propylene oxide) mixed polymeric micelles. Nanomedicine 7, 624-637 (2011).
30. Rabel SR, Sun S, Maurin MB, Patel M. Electronic and resonance effects on the ionization of structural analogues of efavirenz. AAPS PharmSci 3, 26-29 (2001).
31. NIH. NIH Guide for the Care and Use of Laboratory Animals, Publication No. 85-3. NIH, MD, USA (1985).
32. Aimone LD. Overview of pharmacokinectics. Curr. Protoc. Pharmacol. Chapter 7, Unit 7.1 (2005).
33. Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. Int. J. Pharm. 377, 185-198 (2009).
34. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classfication system. Eur. J. Pharm. Sci. 29, 278-287 (2006).
35. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int. J. Pharm. 51, 9-17 (1989).
36. Rabinow BE. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, 785-796 (2004). •• Very relevant review on the prospects of pure drug nanoparticles as innovative pharmaceutical products.
37. Sun W, Tian W, Zhang Y, He J, Mao S, Fang L. Effect of novel stabilizers - cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals. Nanomedicine 8, 460-467 (2012).
38. Thanou M, Verhoef JC, Junginger HE. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 50(Suppl. 1), S91-S101 (2001).
39. Andrade F, Goycoolea F, Chiappetta DA, das Neves J, Sosnik A, Sarmento B. Chitosan-grafted copolymers and chitosan-ligand conjugates as matrices for pulmonary drug delivery. Int. J. Carbohyd. Chem. Article ID 865704 (2011).
40. Chan H-K, Kwok PCL. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 63, 406-416 (2011). • Comprehensive review on the different methods to produce pure drug nanoparticles by bottom-up techniques and the properties of the obtained products.
41. Das S, Ng WK, Kanaujia P, Kim S, Tan RBH. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf. B Biointerfaces 88, 483-489 (2011).
42. Seremeta KP, Chiappetta DA, Sosnik A. Poly(ecaprolactone), Eudragit® RS 100 and poly(ε-caprolactone)/Eudragit® RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz. Colloids Surf. B Biointerfaces 102, 441-449 (2013).
43. Chin-San W. A comparison of the structure, thermal properties, and biodegradability of polycaprolactone/chitosan and acrylic acid grafted polycaprolactone/chitosan. Polymer 46, 147-155 (2005).
44. Gotelli G, Bonelli P, Abraham G, Sosnik A. Fast and efficient synthesis of high molecular weight poly(epsilon-caprolactone) diols by microwave-assisted polymer synthesis (MAPS). J. Appl. Polym. Sci. 121, 1321-1329 (2011).
45. Shown I, Banerjee S, Ramchandran AV, Geckeler KE, Murthy CN. Synthesis of cyclodextrin and sugar-based oligomers for the efavirenz drug delivery. Macromol. Symp. 287, 51-59 (2010).
46. de L Gomes EC, Mussel WN, Resende JM, Fialho SL, Barbosa J, Yoshida MI. Chemical interactions study of antiretroviral drugs efavirenz and lamivudine concerning the development of stable fixed-dose combination formulations for AIDS treatment. J. Braz. Chem. Soc. 24, 573-579 (2013).
47. Sosnik A, Cohn D. Poly(ethylene glycol-poly(epsilon-caprolactone) block oligomers as injectable materials. Polymer 44, 7033-7042 (2003).
48. Schmidt M, Kusche R, Issendorff BV, Haberland H. Irregular variations in the melting point of size-selected atomic clusters. Nature 393, 238-240 (1998).
49. Shin IG, Kim SY, Lee YM, Cho CS, Sung YK. Methoxy poly(ethylene glycol)/epsilon-caprolactone amphiphilic block copolymeric micelle containing indomethacin: I. preparation and characterization. J. Control. Release 51, 1-11 (1998).
50. Cohn D, Lando G, Sosnik A, Garty S, Levi A. Novel degradable reverse thermoresponsive multiblock copolymers. Biomaterials 27, 1718-1727 (2006).
51. das Neves J, Michiels J, Arien KK et al. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm. Res. 29, 1468-1484 (2012).
52. Balani SK, Kauffman LR, Deluna FA, Lin JH. Non-linear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Drug Metabol. Disp. 27, 141-145 (1999).
53. Viljoen M, Gous H, Kruger HS, Riddick A, Meyers TM, Rheeders M. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. AIDS Res. Hum. Retroviruses 26, 613-619 (2010).
54. Semete B, Booysen L, Lemmer Y et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 6, 662-671 (2010).
55. Sarmento B, Mazzaglia D, Bonferoni MC, Neto AP, Monteiro M, Seabra V. Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. Carbohydr. Polym. 84, 919-925 (2011)
56. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int. J. Pharm. 317, 82-89 (2006).
57. Tokiwa Y, Suzuki T. Hydrolysis of polyesters by lipases. Nature 270, 76-78 (1997).
58. Bhavsar MD, Amiji MM. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech 9, 288-294 (2008).
59. Sosnik A, Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Adv. Drug Deliv. Rev. 62, 375-377 (2010).
60. Williams J, Sayles HR, Meza JL et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond.) 8(11), 1807-1813 (2013).
61. Rathbun RC, Greenfield RA. Antiretroviral therapy for HIV infection. http://emedicine.medscape.com/article/1533218-overview
62. AIDSinfo. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK (2002). Guidelines for using antiretroviral agents among HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines
63. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 revision. http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf
64. AIDSinfo. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://aidsinfo.nih.gov/ContentFiles/lvguidelines/PediatricGuidelines.pdf